We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Cesca Therapeutics Inc | NASDAQ:KOOL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 5.14 | 3.30 | 5.22 | 0 | 00:00:00 |
From Dec 2019 to Dec 2024
RANCHO CORDOVA, Calif., Sept. 3, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10 at 12:30 pm ET. The conference is being held September 8-10 at the Lotte New York Palace Hotel.
Management will also be available for one-on-one meetings with institutional investors who are registered to attend the conference. Institutional investors who would like to attend Cesca's presentation or meet with management can register through the H.C. Wainwright conference portal or contact Rx Communications to schedule a meeting.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The company has developed an automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market. For more information about Cesca, please visit: www.CescaTherapeutics.com. For additional information about ThermoGenesis, please visit: www.thermogenesis.com.
Company Contact:
Wendy Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original content:http://www.prnewswire.com/news-releases/cesca-therapeutics-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300910094.html
SOURCE Cesca Therapeutics Inc.
Copyright 2019 PR Newswire
1 Year Cesca Therapeutics Chart |
1 Month Cesca Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
